EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.
Lupberger J; Zeisel MB; Xiao F; Thumann C; Fofana I; Zona L; Davis C; Mee CJ; Turek M; Gorke S; Royer C; Fischer B; Zahid MN; Lavillette D; Fresquet J; Cosset FL; Rothenberg SM; Pietschmann T; Patel AH; Pessaux P; Doffoël M; Raffelsberger W; Poch O; McKeating JA; Brino L; Baumert TF; Nature Medicine, 2011, vol. 17, issue 5, p 589, ISSN 1546170x. ISBN 1546170x.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef